Active Biotech, a Sweden-based biopharmaceutical company that is developing therapies for autoimmune diseases, inflammatory diseases, and cancers, recently announced that it is partnering with Teva Pharmaceutical Industries Ltd. to develop a new, experimental drug for treating Huntington’s disease. The two companies will work together to launch a new phase 2 clinical trial…
Teva, Active Biotech Partner To Develop Laquinimod For Huntington’s Disease
Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
Recent Posts
- Trial, error, and toe covers: Learning to adapt in life with ALS
- 5-year survival seen for over 40% of ALS patients on masitinib in trial
- Long-term air pollution exposure shows no clear link to ALS in UK study
- Masitinib trial insurance offers a safety net for ALS research
- Spontaneous mutations may underlie some sporadic ALS cases